Billiontoone (NASDAQ:BLLN) Earns Equal Weight Rating from Analysts at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Billiontoone (NASDAQ:BLLN) in a report issued on Monday, Marketbeat reports. The brokerage issued an equal weight rating and a $110.00 price target on the stock.

Several other research firms have also recently weighed in on BLLN. JPMorgan Chase & Co. started coverage on Billiontoone in a report on Monday. They set an “overweight” rating and a $150.00 price objective on the stock. Piper Sandler assumed coverage on shares of Billiontoone in a research note on Monday. They issued an “overweight” rating and a $150.00 price target on the stock. Stifel Nicolaus started coverage on shares of Billiontoone in a research report on Monday. They set a “buy” rating and a $145.00 price objective for the company. BTIG Research began coverage on shares of Billiontoone in a research report on Monday. They issued a “buy” rating and a $160.00 price objective on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Billiontoone in a research note on Monday. They issued a “hold” rating and a $117.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $138.67.

Billiontoone Trading Down 10.6%

BLLN stock opened at $102.76 on Monday. Billiontoone has a 1-year low of $88.00 and a 1-year high of $138.70.

About Billiontoone

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.